Suez, Daniel <br/><br/>
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents.  [electronic resource] 

 -  Immunotherapy  08 2019 
 - 1057-1065 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1750-7448 
<br/><br/><label>Standard No.: </label>10.2217/imt-2019-0057  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Child<br/>Child, Preschool<br/>Drug-Related Side Effects and Adverse Reactions--epidemiology<br/>Europe<br/>Female<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Injections, Subcutaneous<br/>Male<br/>Middle Aged<br/>North America<br/>Primary Immunodeficiency Diseases--drug therapy<br/>Prospective Studies<br/>Young Adult